Clinical Trials Directory

Trials / Completed

CompletedNCT00707187

Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction

Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial of the Efficacy and Safety of IC351 in Female Patients With Raynaud Phenomenon and Female Sexual Dysfunction Secondary to Systemic Sclerosis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
120 (actual)
Sponsor
University of Medicine and Dentistry of New Jersey · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Purpose of the study is to evaluate the effectiveness and safety of a new investigational dur, IC351. Study is designed to gather information regarding the possible usefulness of IC351 as a treatment of several blood vessel features of scleroderma. This includes Raynaud phenomenon as well as the vaginal dryness and discomfort associated with scleroderma

Conditions

Interventions

TypeNameDescription
DRUGCialis35 pills of study medication (20 mg)

Timeline

Start date
2001-07-01
Primary completion
2002-07-01
Completion
2002-07-01
First posted
2008-06-30
Last updated
2008-06-30

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00707187. Inclusion in this directory is not an endorsement.